Other Streetwise ReportsThe Gold Report The Energy Report The Life Sciences Report The Mining Report
Today's Featured Company
BrainStorm Cell Therapeutics Inc.: (BCLI:NASDAQ) BrainStorm Cell Therapies Inc. is developing a platform technology based on autologous mesenchymal stem cells that have been induced to secrete a variety of neurotrophic factors. The company is in a Phase 2 trial in ALS after having seen excellent safety and efficacy in earlier clinical studies. More >
Streetwise Expert Interviews
As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next
Steve Brozak sees a bubble getting larger, and he is anticipating the time when biotech stocks pull back to take a breather, like all high-flying markets ultimately do. While investors may own innovative companies with highly disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this interview with The Life Sciences Report, Brozak, president and managing partner at WBB Securities, showcases six names with strong immunotherapeutic platforms that he believes have extraordinary potential to reward investors many times over.(5/27/15) More >
Exceptional Management and Disruptive Products Top the Investment Checklist for Vista Partners' Ross
Investing in micro- and small-cap biotech companies carries great risk, but for investors who take the time to dig out the value proposition, Ross Silver of Vista Partners asserts the upside can be phenomenal. (5/20/15) More >
Learn More About Companies in This Issue
|Alliance for Regenerative Medicine|
BrainStorm Cell Therapeutics Inc.
RepliCel Life Sciences Inc.
|Nobilis Health Corp.|